diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12988diaendo-12988Research ArticleНовостиNewsНа пути к профилактике сахарного диабета 1 типа: зарегистрирован первый в истории препарат, замедляющий развитие аутоиммунного процессаTowards prevention of type 1 diabetes: FDA approved first drug with potential to delay clinical stage of diseasehttps://orcid.org/0000-0002-4316-8546ЛаптевД. Н.LaptevD. N.

Лаптев Дмитрий Никитич, д.м.н.

Researcher ID: O-1826-2013; Scopus Author ID: 24341083800; eLibrary SPIN: 2419-4019

117036, Москва, ул. Дмитрия Ульянова, д. 11

Dmitry N. Laptev, MD, PhD

Researcher ID: O-1826-2013; Scopus Author ID: 24341083800; eLibrary SPIN: 2419-4019

11, Dm. Ul’yanova street, 117036 Moscow

laptevdn@ya.ruhttps://orcid.org/0000-0002-8175-7886ДедовИ. И.DedovI. I.

Дедов Иван Иванович, профессор, д.м.н., академик РАН

Researcher ID: D-3729-2014; Scopus Author ID: 7101843976; eLibrary SPIN: 5873-2280

Москва

Ivan I. Dedov, MD, PhD, Professor, Academician of the Russian Academy of Sciences

Researcher ID: D-3729-2014; Scopus Author ID: 7101843976; eLibrary SPIN: 5873-2280

Moscow

dedov@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202228122022256576579Copyright © Лаптев Д.Н., Дедов И.И., 20232023Лаптев Д.Н., Дедов И.И.Laptev D.N., Dedov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12988

Принимая во внимание высокую вероятность неблагоприятных исходов у пациентов с сахарным диабетом 1 типа (СД1), а также бремя, создаваемое болезнью, поиск методов, предупреждающих разрушение бета-клеток, имеет первостепенное значение. До недавнего времени все попытки иммунотерапевтических вмешательств не достигали существенных успехов, позволяя в лучшем случае уменьшить скорость разрушения бета-клеток, не останавливая иммунный процесс и не позволяя нормализовать гликемию. В ноябре 2022 г. Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило препарат теплизумаб для замедления развития клинической стадии СД1. Целью публикации является оценка результатов применения препарата теплизумаб у людей на второй (доклинической) стадии СД1, а также рассмотрение дальнейших перспектив данного лечения.

Given the increased morbidity and mortality in patients with type 1 diabetes mellitus (T1DM), as well as the burden posed by the disease, the search for methods to prevent the destruction of beta cells is of paramount importance. Until recently, no attempts of immunotherapeutic interventions have achieved significant success, allowing at best reducing the rate of destruction of beta cells without stopping the immune process and not allowing normalization of glycemia. In November 2022, the U.S. Food and Drug Administration (FDA) approved the drug teplizumab to delay clinical diagnosis of T1DM. The purpose of the publication is to evaluate the results of teplizumab treatment in high-risk participants with the second (preclinical) stage of T1DM, as well as to consider further prospects for this treatment.

сахарный диабет 1 типаиммунотерапияпрофилактикаТ-клеткиtype 1 diabetes mellitusimmunotherapypreventionT-cellsReferencesFDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes Accessed November 18, 2022.FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes Accessed November 18, 2022.Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. doi: https://doi.org/10.1126/scitranslmed.abc8980Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. doi: https://doi.org/10.1126/scitranslmed.abc8980Waldron-Lynch F, Henegariu O, Deng S, et al. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Sci Transl Med. 2012;4(118). doi: https://doi.org/10.1126/scitranslmed.3003401Waldron-Lynch F, Henegariu O, Deng S, et al. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Sci Transl Med. 2012;4(118). doi: https://doi.org/10.1126/scitranslmed.3003401Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514-518. doi: https://doi.org/10.1038/nature10228Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514-518. doi: https://doi.org/10.1038/nature10228Дедов И.И., Шестакова М.В. Сахарный диабет типа 1: реалии и перспективы. М.: ООО «Издательство «Медицинское информационное агентство», 2016. 504 c.Dedov II, Shestakova MV. Type 1 diabetes mellitus: realities and prospects. Moscow: OOO Publishing House Medical Information Agency, 2016. 504 p. (In Russ.).Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet Lond Engl. 2014;383(9911):69-82. doi: https://doi.org/10.1016/S0140-6736(13)60591-7Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet Lond Engl. 2014;383(9911):69-82. doi: https://doi.org/10.1016/S0140-6736(13)60591-7Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-3774. doi: https://doi.org/10.2337/db13-0345Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-3774. doi: https://doi.org/10.2337/db13-0345Lord S, Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. F1000Research. 2020;9:827. doi: https://doi.org/10.12688/f1000research.21801.1Lord S, Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. F1000Research. 2020;9:827. doi: https://doi.org/10.12688/f1000research.21801.1Hagopian W, Ferry RJ, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908. doi: https://doi.org/10.2337/db13-0236Hagopian W, Ferry RJ, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908. doi: https://doi.org/10.2337/db13-0236Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi: https://doi.org/10.2337/dc15-1419Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi: https://doi.org/10.2337/dc15-1419Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol Baltim Md 1950. 1997;158(6):2947-2954.Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol Baltim Md 1950. 1997;158(6):2947-2954.Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383-1395. doi: https://doi.org/10.1056/NEJMoa0904492Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383-1395. doi: https://doi.org/10.1056/NEJMoa0904492Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet Lond Engl. 2008;372(9636):375-382. doi: https://doi.org/10.1016/S0140-6736(08)61000-4Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet Lond Engl. 2008;372(9636):375-382. doi: https://doi.org/10.1016/S0140-6736(08)61000-4Tucker ME. With Type 1 Diabetes Delay Possible, Focus Now on Screening. Available at: www.medscape.com. Published November 30, 2022. Accessed November 30, 2022.Tucker ME. With Type 1 Diabetes Delay Possible, Focus Now on Screening. Available at: www.medscape.com. Published November 30, 2022. Accessed November 30, 2022.

The authors declare that there are no conflicts of interest present.